Published in Virology on November 10, 1998
A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc Natl Acad Sci U S A (2000) 5.30
Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med (2002) 3.88
Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med (2010) 3.25
Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol (2009) 2.71
Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol (2000) 2.67
Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol (2002) 2.58
Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol (2008) 2.58
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol (2009) 2.41
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine (2008) 2.33
Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis (2002) 2.26
Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A (2003) 2.18
Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J Virol (2000) 2.09
Heterologous gene expression from transmissible gastroenteritis virus replicon particles. J Virol (2002) 1.85
Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol (2006) 1.85
Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis (2011) 1.82
Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol (2008) 1.78
Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol (2010) 1.77
Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol (2001) 1.66
Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines (2011) 1.62
Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs (2013) 1.57
An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol (2003) 1.56
Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J Virol (2000) 1.52
Animal models for Ebola and Marburg virus infections. Front Microbiol (2013) 1.51
The efficient packaging of Venezuelan equine encephalitis virus-specific RNAs into viral particles is determined by nsP1-3 synthesis. Virology (2005) 1.51
Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J Virol (2002) 1.36
Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J Virol (2005) 1.35
Forty-five years of Marburg virus research. Viruses (2012) 1.34
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis (2012) 1.32
Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol (2010) 1.29
Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol (2007) 1.24
Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system. J Virol (2003) 1.23
Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J Virol (2010) 1.22
Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect Immun (2001) 1.20
Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A (2005) 1.16
Alphavirus replicon approach to promoterless analysis of IRES elements. Virology (2006) 1.15
Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol (2013) 1.11
Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins. Clin Vaccine Immunol (2007) 1.08
Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine (2009) 1.08
Mouse models for filovirus infections. Viruses (2012) 1.07
Clinical aspects of Marburg hemorrhagic fever. Future Virol (2011) 1.06
Activation of triggering receptor expressed on myeloid cells-1 on human neutrophils by marburg and ebola viruses. J Virol (2006) 1.05
Intracellular events and cell fate in filovirus infection. Viruses (2011) 1.01
Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge. Infect Immun (2003) 1.00
Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLoS Negl Trop Dis (2013) 0.99
Filovirus vaccines. Hum Vaccin (2011) 0.98
An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice. J Virol (2007) 0.95
Potential vaccines and post-exposure treatments for filovirus infections. Viruses (2012) 0.94
Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice. Vaccine (2011) 0.92
Vaccination of mice with gonococcal TbpB expressed in vivo from Venezuelan equine encephalitis viral replicon particles. Infect Immun (2006) 0.92
Advances in virus-like particle vaccines for filoviruses. J Infect Dis (2011) 0.92
Correlates of immunity to filovirus infection. Viruses (2011) 0.91
Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus. J Virol (2014) 0.91
Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. Cancer Res (2010) 0.90
A nonhuman primate scrub typhus model: protective immune responses induced by pKarp47 DNA vaccination in cynomolgus macaques. J Immunol (2015) 0.90
Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. Hum Vaccin Immunother (2015) 0.86
Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis. Breast Cancer Res (2004) 0.85
Analysis of Venezuelan equine encephalitis replicon particles packaged in different coats. PLoS One (2008) 0.84
Alphavirus-based vaccines. Viruses (2014) 0.84
Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever. J Biomed Biotechnol (2011) 0.84
High-throughput virtual screening and docking studies of matrix protein vp40 of ebola virus. Bioinformation (2013) 0.83
Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses. J Virol (2014) 0.79
Discovery of common marburgvirus protective epitopes in a BALB/c mouse model. Virol J (2009) 0.79
Filoviruses: One of These Things is (not) Like the Other. Viruses (2015) 0.78
Mechanisms of immunity in post-exposure vaccination against Ebola virus infection. PLoS One (2015) 0.78
A tetravalent alphavirus-vector based dengue vaccine provides effective immunity in an early life mouse model. Vaccine (2014) 0.76
Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge. PLoS One (2016) 0.75
Cell-targeting antibodies in immunity to Ebola. Pathog Dis (2016) 0.75
The Role of Cytokines and Chemokines in Filovirus Infection. Viruses (2015) 0.75
Global research trends of World Health Organization's top eight emerging pathogens. Global Health (2017) 0.75
Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges). Viruses (2016) 0.75
Ebola and Marburg virus vaccines. Virus Genes (2017) 0.75
The Ensembl genome database project. Nucleic Acids Res (2002) 40.87
Ensembl 2009. Nucleic Acids Res (2008) 25.38
Ensembl 2008. Nucleic Acids Res (2007) 20.67
Ensembl 2007. Nucleic Acids Res (2006) 20.10
Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science (1999) 18.55
Ensembl 2005. Nucleic Acids Res (2005) 15.13
Ensembl 2002: accommodating comparative genomics. Nucleic Acids Res (2003) 12.26
Ensembl 2004. Nucleic Acids Res (2004) 11.88
Ensembl 2006. Nucleic Acids Res (2006) 11.66
Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Mol Cell Biol (2001) 6.68
Pathology of fatal West Nile virus infections in native and exotic birds during the 1999 outbreak in New York City, New York. Vet Pathol (2000) 6.46
RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85
Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis (1994) 5.44
Redesigning health care. BMJ (2001) 5.43
Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood (2000) 5.06
Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst (2004) 4.83
Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature (1984) 4.28
Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol (1994) 4.27
TB policy and the badger culling trials. Vet Rec (2006) 4.14
Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med (2000) 4.14
The clinical and laboratory diagnosis of Trichomonas vaginalis infection. Sex Transm Dis (1981) 3.89
TB policy and the badger culling trials. Vet Rec (2006) 3.84
The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry (1990) 3.75
Systematic review of multidisciplinary interventions in heart failure. Heart (2005) 3.68
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet (2002) 3.67
Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol (2001) 3.53
The "redisorganisation" of the NHS. BMJ (2001) 3.52
Effect of low-level body burdens of lead on the mental development of children: limitations of meta-analysis in a review of longitudinal data. Arch Environ Health (1992) 3.42
Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. Clin Microbiol Infect (2004) 3.27
Cervical screening in Perth and Kinross since introduction of the new contract. BMJ (1991) 3.20
A low resolution structure for the histone core of the nucleosome. Nature (1980) 3.17
Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg (1995) 3.08
Public health gets a boost in NHS streamlining. BMJ (1994) 3.03
WEIL'S DISEASE (LEPTOSPIROSIS): A CLINICAL AND BACTERIOLOGICAL STUDY OF NINETEEN CASES OCCURRING CHIEFLY AMONG FISH WORKERS. Br Med J (1934) 2.99
The dynamics of chromosome evolution in birds and mammals. Nature (1999) 2.95
Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet (1998) 2.90
Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J Immunol (1997) 2.89
Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. Am J Clin Nutr (1983) 2.89
Women prefer hospital births. BMJ (1992) 2.88
Competing demands from physical problems: effect on initiating and completing depression care over 6 months. Arch Fam Med (2001) 2.77
MvirDB--a microbial database of protein toxins, virulence factors and antibiotic resistance genes for bio-defence applications. Nucleic Acids Res (2006) 2.76
The role of competing demands in the treatment provided primary care patients with major depression. Arch Fam Med (2000) 2.75
Analysis of individual human trigeminal ganglia for latent herpes simplex virus type 1 and varicella-zoster virus nucleic acids using real-time PCR. J Virol (2000) 2.70
Rapid geographic spread of a methicillin-resistant Staphylococcus aureus strain. Clin Infect Dis (1997) 2.65
Results of provider self-adjudication using the prudent layperson standard compared with the managed care organization's emergency department claim review process. Ann Emerg Med (2000) 2.64
Kinetic tuning of myosin via a flexible loop adjacent to the nucleotide binding pocket. J Biol Chem (1998) 2.62
The purified yeast pre-mRNA splicing factor PRP2 is an RNA-dependent NTPase. EMBO J (1992) 2.60
Langerhans cell (eosinophilic) granulomatosis. A clinicopathologic study encompassing 50 years. Am J Surg Pathol (1996) 2.60
London's health care again. BMJ (1992) 2.56
Improving depression outcomes in community primary care practice: a randomized trial of the quEST intervention. Quality Enhancement by Strategic Teaming. J Gen Intern Med (2001) 2.56
Improving London's health service. BMJ (1993) 2.50
Anthropometric measurement of muscle mass: revised equations for calculating bone-free arm muscle area. Am J Clin Nutr (1982) 2.41
Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. CMAJ (1997) 2.41
Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses. Cell (2001) 2.39
Gift authorship: a poisoned chalice? BMJ (1994) 2.30
Medical students' clinical self-assessments: comparisons with external measures of performance and the students' self-assessments of overall performance and effort. Acad Med (1993) 2.30
Dominance in lambda S mutations and evidence for translational control. J Mol Biol (1988) 2.24
NHS reorganisation. Cause and effect. Health Serv J (2001) 2.23
American Orthopaedic Foot and Ankle Society women's shoe survey. Foot Ankle (1993) 2.23
Is age-related stability of subjective well-being a paradox? Cross-sectional and longitudinal evidence from the Berlin Aging Study. Psychol Aging (2000) 2.20
Dissociation of Pavlovian and instrumental incentive learning under dopamine antagonists. Behav Neurosci (2000) 2.18
Clinical disease, drug susceptibility, and biochemical patterns of the unnamed third biovariant complex of Mycobacterium fortuitum. J Infect Dis (1991) 2.17
Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial. J Clin Oncol (2001) 2.16
Ezrin is a cyclic AMP-dependent protein kinase anchoring protein. EMBO J (1997) 2.16
Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A (1999) 2.14
The Abbott IMx automated benchtop immunochemistry analyzer system. Clin Chem (1988) 2.12
What do peer reviewers do? JAMA (1990) 2.11
A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatr Scand (1994) 2.10
Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (1997) 2.08
Outbreak of low pathogenicity H7N3 avian influenza in UK, including associated case of human conjunctivitis. Euro Surveill (2006) 2.08
Evidence-based recommendations for the use of Negative Pressure Wound Therapy in traumatic wounds and reconstructive surgery: steps towards an international consensus. Injury (2011) 2.07
Self-poisoning and self-injury in the Oxford area. Epidemiological aspects 1969-73. Br J Prev Soc Med (1975) 2.06
Geographical distribution of preconceptional radiation doses to fathers employed at the Sellafield nuclear installation, West Cumbria. BMJ (1993) 2.05
Preventing fraud. BMJ (1991) 2.04
Determination of metronidazole and its two major metabolites in biological fluids by high pressure liquid chromatography. Br J Clin Pharmacol (1978) 2.03
TB policy and the ISG's findings. Vet Rec (2007) 2.02
DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology (1998) 2.02
Procyclic acidic repetitive protein (PARP) genes located in an unusually small alpha-amanitin-resistant transcription unit: PARP promoter activity assayed by transient DNA transfection of Trypanosoma brucei. Mol Cell Biol (1990) 2.01
Predictors of psychological adjustment in school-age children infected with HIV. J Pediatr Psychol (2001) 2.01
pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol (1998) 2.01
Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis (1997) 2.00
Comparison of patients' needs for information on prostate surgery with printed materials provided by surgeons. Qual Health Care (1995) 2.00
Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob Agents Chemother (1990) 1.96
Community prevalence survey of children's blood lead levels and environmental lead contamination in inner Sydney. Med J Aust (1992) 1.95
Hyperactivity and delay aversion--I. The effect of delay on choice. J Child Psychol Psychiatry (1992) 1.95
Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine (2000) 1.95
Genetic control of hexose phosphate uptake by Escherichia coli. Nature (1969) 1.94
Cryptosporidiosis in a veterinary student. J Am Vet Med Assoc (1982) 1.93
A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. N Engl J Med (1994) 1.93
Recruitment in the Cooperative Study of Sickle Cell Disease (CSSCD). Control Clin Trials (1987) 1.93
First report on chicken genes and chromosomes 2000. Cytogenet Cell Genet (2000) 1.92
Duplicate publication. BMJ (1992) 1.91
The sex ratio of children in relation to paternal preconceptional radiation dose: a study in Cumbria, northern England. J Epidemiol Community Health (1996) 1.88
Keeping confidences in published papers. BMJ (1991) 1.86
Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med (1991) 1.86
Planning for the future: the experience of implementing a children's day assessment unit in a district general hospital. Arch Dis Child (1997) 1.83
Rating the burn scar. J Burn Care Rehabil (1990) 1.82
Heterogeneity of Trichomonas vaginalis and discrimination among trichomonal isolates and subpopulations with sera of patients and experimentally infected mice. Infect Immun (1985) 1.81
Incidence and causes of rectal bleeding in general practice as detected by colonoscopy. Br J Gen Pract (1996) 1.78
Comparison of the pharmacokinetics of metronidazole in healthy female volunteers following either a single oral or intravenous dose. Br J Clin Pharmacol (1979) 1.76